Modality
mAb
MOA
Anti-Tau
Target
MET
Pathway
Hedgehog
Parkinson's
Development Pipeline
Preclinical
~Jul 2015
→ ~Oct 2016
Phase 1
~Jan 2017
→ ~Apr 2018
Phase 2
Jul 2018
→ Jun 2026
Phase 2Current
NCT05910236
2,450 pts·Parkinson's
2018-07→2026-01·Active
NCT07850084
1,965 pts·Parkinson's
2023-11→2026-06·Recruiting
4,415 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-01-133mo agoPh3 Readout· Parkinson's
2026-06-052mo awayPh3 Readout· Parkinson's
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P2/3
Active
P2/3
Recruit…
Catalysts
Ph3 Readout
2026-01-13 · 3mo ago
Parkinson's
Ph3 Readout
2026-06-05 · 2mo away
Parkinson's
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05910236 | Phase 2/3 | Parkinson's | Active | 2450 | OS |
| NCT07850084 | Phase 2/3 | Parkinson's | Recruiting | 1965 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| RVM-274 | Revolution Medicines | Phase 3 | MET | |
| Voxamavacamten | Corcept | Approved | BET |